X4 Pharmaceuticals Inc
XFOR
Company Profile
Business description
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Contact
61 North Beacon Street
4th Floor
BostonMA02134
USAT: +1 857 529-8300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
143
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,743.60 | 30.00 | -0.34% |
| CAC 40 | 7,691.55 | 134.24 | 1.78% |
| DAX 40 | 24,033.22 | 383.92 | 1.62% |
| Dow JONES (US) | 43,819.27 | 432.43 | 1.00% |
| FTSE 100 | 8,798.91 | 63.31 | 0.72% |
| HKSE | 24,284.15 | 41.25 | -0.17% |
| NASDAQ | 20,273.46 | 105.55 | 0.52% |
| Nikkei 225 | 40,150.79 | 566.21 | 1.43% |
| NZX 50 Index | 12,583.59 | 103.54 | 0.83% |
| S&P 500 | 6,173.07 | 32.05 | 0.52% |
| S&P/ASX 200 | 8,514.20 | 36.60 | -0.43% |
| SSE Composite Index | 3,424.23 | 24.23 | -0.70% |